Dr Tim Boyle joined ARCS Australia as CEO in November 2023, previously serving in senior leadership and executive roles at ANSTO. A recognized leader in research translation and IP commercialisation, he has over two decades of experience in technology licensing and developing science based ventures. Previously Tim also served as Executive Chair of ATTP, and is a life member and former non-executive director of Knowledge Commercialisation Australasia. Tim also holds appointments as an Adjunct Professor at Swinburne University of Technology, and Global Expert Faculty at Singularity University.

Margaret is a seasoned industry professional, having spent valuable time in drug discovery, drug development and the last 25 years in Regulatory Affairs with some of the largest global pharma companies. Margaret has gained a wealth of hands-on experience in developing innovative strategies for bringing new products to market in Australia and the US. Running a bespoke consulting company for the last 21 year has given her the privilege to lead a team of exceptionally talented and experienced professionals, each of whom has 25-30 years’ experience in the biotech and pharma industries. Margaret is a results focussed, customer focused, strategic regulatory professional, with demonstrated positive, productive relationships within the industry.

Christopher Burns (B.Sc. (Hons) PhD FRACI FRSC GAICD) – CEO and Managing Director Chris is an experienced drug discovery leader having worked in various roles in pharma, biotech and academia for over 30 years. After completing a Ph. D. in Organic Chemistry at the University of Melbourne, Chris undertook postdoctoral studies in the USA before moving to Pfizer UK, as a senior scientist. After 5 years he returned to Australia as a Research Fellow at the University of Sydney with the CRC for Molecular Engineering and Technology and after two years moved to the biotechnology company Ambri as Head of Chemistry. Chris then moved to the Melbourne-based biotech Cytopia as Head of Medicinal Chemistry and later as Research Director. Over this time he led teams in the discovery of two anti-cancer agents that entered clinical trial (including the drug momelotinib which was recently approved by the US FDA). Chris was subsequently recruited to the Walter and Eliza Hall Institute of Medical Research in Melbourne as a Laboratory Head before taking on executive and leadership roles with a number of privately-held biotechnology companies in Melbourne including Certa Therapeutics and MycRx. Dr Burns is the inventor on over 30 patents and a co-author on over 65 scientific publications, and is a Fellow of the Royal Society of Chemistry (UK) and the Royal Australian Chemical Institute. He was the recipient of the 2022 Adrien Albert Award - the premier award of the MCCB Division of the Royal Australian Chemical Institute which is given for sustained, outstanding research in the field of medicinal chemistry or chemical biology. Dr Burns is a founder of Amplia Therapeutics and originally served as a Non-Executive Director from 2018 and was subsequently appointed as Chief Executive Officer and Managing Director in December 2022.